bay x 1005 has been researched along with Bronchial Hyperreactivity in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Matsuo, A; Nagai, H; Takeda, H; Tanaka, H; Uno, T | 1 |
| Hamilton, AL; O'Byrne, PM; Watson, RM; Wyile, G | 1 |
1 trial(s) available for bay x 1005 and Bronchial Hyperreactivity
| Article | Year |
|---|---|
Attenuation of early and late phase allergen-induced bronchoconstriction in asthmatic subjects by a 5-lipoxygenase activating protein antagonist, BAYx 1005.
Topics: Adult; Area Under Curve; Asthma; Bronchial Hyperreactivity; Bronchial Provocation Tests; Cross-Over Studies; Double-Blind Method; Female; Forced Expiratory Volume; Humans; Lipoxygenase Inhibitors; Male; Methacholine Chloride; Quinolines | 1997 |
1 other study(ies) available for bay x 1005 and Bronchial Hyperreactivity
| Article | Year |
|---|---|
Effect of a novel leukotoriene synthesis inhibitor, BAY x1005, on the antigen-and LPS-induced airway hyperresponsiveness in guinea pigs.
Topics: Acetylcholine; Animals; Antigens; Bronchial Hyperreactivity; Bronchoalveolar Lavage Fluid; Guinea Pigs; Humans; Leukotrienes; Lipopolysaccharides; Lipoxygenase Inhibitors; Male; Quinolines; Trachea | 1996 |